Celldex Therapeutics (CLDX) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Celldex Therapeutics has completed a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria. The study aimed to evaluate the clinical effects, safety, and pharmacokinetics of barzolvolimab (CDX-0159) in patients who continue to experience symptoms despite using H1-antihistamines. This research is significant as it targets a patient group with limited treatment options, potentially offering a new therapeutic pathway.
The study tested barzolvolimab, a biological treatment administered subcutaneously, in doses of 150 mg and 300 mg, compared to a placebo. The intervention’s goal is to alleviate symptoms in patients with Chronic Inducible Urticaria, a condition characterized by persistent hives triggered by external factors.
The study followed a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcome assessors were all blinded to the treatment allocations. The primary purpose of the study was treatment-focused, aiming to establish the efficacy and safety of the intervention.
Key milestones for the study include its start date on June 1, 2022, and its completion on November 4, 2025. These dates are crucial as they mark the timeline for data collection and analysis, which investors closely monitor for potential market impacts.
The completion of this study could influence Celldex Therapeutics’ stock performance positively, as successful results may lead to new market opportunities and increased investor confidence. This development is particularly relevant in the context of limited competition in the Chronic Inducible Urticaria treatment space, potentially positioning Celldex as a leader.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.
To learn more about CLDX’s potential, visit the Celldex Therapeutics drug pipeline page.